Vegeplast 1


18 February 2014



Communiqué de presse du 30/01/2014

Algraal project by SEPPIC and VEGEPLAST


January 30, 2014 in Castres SEPPIC meets all partners for the launch of Algraal Project. He was selected as Project of Excellence by the General Directorate for Competitiveness Industry and Services (DGCIS) in the 16th Appeal Single Interministerial Fund (FUI) . 

SEPPIC Algraal the pilot project to develop a new source of fatty alcohol production and emulsifiers algal origin for the cosmetic industry. This project for a period of 3 years , meets 4 industrial partners Seppic leader , Fermentalg THE Mesta , VEGEPLAST and 3 public partners : the University of Le Havre , INP / ENSIACET and INRA.   This labeled with clusters AGRIMIP , TRIMATEC , PASS, and Cosmetic Valley project received funding of € 1.5 million granted by the FUI , regional and local authorities.   Create and develop a raw material “green” and “sustainable” in the production of fatty alcohols and emulsifiers is a major challenge to meet the new demands of market and consumers. Through this project, SEPPIC strengthens its position in Green Chemistry from the French cosmetics industry .   It receives support from some customers SEPPIC as Clarins and Yves Rocher , ready to use this new raw material products in their formulations .       Sandra Manceau , Head of R & D project concludes ” SEPPIC daily commitment to innovation, as part of its sustainable development policy , it has been a priority in its R & D. Focused on green chemistry and plant chemistry , research and development activity involves 15 % of the workforce SEPPIC and represents an investment of 4% of turnover. SEPPIC deposited between 10 and 15 patent applications per year and has a portfolio of more than 140 patent families. The Algraal project exemplifies this commitment. ”       SEPPIC in brief Subsidiary of Air Liquide Group within the Healthcare, SEPPIC develops and markets a wide range of specialty ingredients for health – excipients and active – dedicated to the markets of cosmetics, pharmaceuticals and vaccines. Present in over 70 countries through its subsidiaries and its network of distributors, SEPPIC employs over 600 people worldwide including 100 researchers . Air Liquide’s Healthcare business The World Business Air Liquide Healthcare provides medical gases, services home health , hygiene products , medical equipment and specialty ingredients .

In 2012, it has served more than 7,500 hospitals and 1 million patients at home across the world. The Group also published in 2012 a turnover Health 2 482 million euros , directed by 10,000 employees.


CONTACT SEPPIC Corporate Communications Alexandra Gilbert Tel. + 33 (0) 1 42 91 41 18    World leader in gases , technologies and services for industry and health, Air Liquide is present in 80 countries with approximately 50,000 employees and serves over 2 million customers and patients. Oxygen, nitrogen and hydrogen are the heart of the Group’s business since its inception in 1902. Air Liquide’s ambition is to be the leader in its industry , being efficient in the long term and acting responsibly.   Air Liquide , it is ideas that create value over the long term. The commitment and inventiveness permanent Group employees are at the heart of its development.   Air Liquide expects the major challenges of its markets, invests locally and globally and offers high quality solutions .   The Group relies on its operational competitiveness , its targeted growth markets investment and innovation to deliver profitable growth over time.   Turnover Air Liquide amounted to € 15.3 billion in 2012 . Solutions to protect lives and the environment represent approximately 40% of its sales. Air Liquide is listed on Euronext Paris (compartment A) and is a member of the CAC 40 and Dow Jones Euro Stoxx 50.